<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83954">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01875549</url>
  </required_header>
  <id_info>
    <org_study_id>2013-03-014-002</org_study_id>
    <nct_id>NCT01875549</nct_id>
  </id_info>
  <brief_title>Comparison Between Unilateral Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction to Use a LCD Stent</brief_title>
  <official_title>Comparison Between Unilateral Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction to Use a Large Cell Niti-S (LCD) Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kwang Hyuck Lee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Internal biliary drainage is an useful method for a control of jaundice and cholangitis to
      patients who had a malignant hilar obstruction due to hepatocellular carcinoma,
      cholangiocarcinoma, gall bladder cancer or metastatic lymphadenopathy.

      Bilateral biliary drainage is more physiologic but technically difficult to compared with
      unilateral biliary drainage specially related to conformability and flexibility between
      using stents.

      There are no prospective clinical trials compared with these internal biliary drainage
      methods in hilar malignant obstruction using metal stent.

      Therefore, the investigators want to compare the clinical outcome of two method: Unilateral
      biliary stent and Bilateral biliary stent
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Stent patency</measure>
    <time_frame>up to 1year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Participants will followed for the new obstruction(new jaundice) will occur.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival period</measure>
    <time_frame>up to 1year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Participants will followed for 1year.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>complication</measure>
    <time_frame>up to 1year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Participants will followed after stent insertion and observe a complication rate between two groups.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Obstruction of Biliary Tree</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Malignant Lymphadenopathy</condition>
  <condition>Gall Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Unilateral stent insertion group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the use of unilateral stent insertion in malignant hilar obstruction for using endoscopic retrograde cholangiopancreatography(ERCP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bilateral stent insertion group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the use of bilateral stent insertion in malignant hilar obstruction for using endoscopic retrograde cholangiopancreatography(ERCP)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>stent insertion</intervention_name>
    <description>to use a LCD stent at an unilateral or bilateral stent insertion</description>
    <arm_group_label>Unilateral stent insertion group</arm_group_label>
    <arm_group_label>Bilateral stent insertion group</arm_group_label>
    <other_name>Niti-S large cell D-type biliary stent [LCD]</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic retrograde cholangiopancreatoscopy(ERCP)</intervention_name>
    <description>to use ERCP for a stent insertion in an obstructive biliary tract</description>
    <arm_group_label>Unilateral stent insertion group</arm_group_label>
    <arm_group_label>Bilateral stent insertion group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt; 18

          -  diagnosis of malignancy in pathology or cytology

          -  jaundice(Total bilirubin)&gt; 2.0 mg/dL

          -  Diagnosed malignant hilar invasion to CT or other image finding

        Exclusion Criteria:

          -  bleeding tendency(INR&gt;1.5)

          -  Pregnancy

          -  severe liver,kidney disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kwang hyuck Lee, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Division of Gastroenterology,Department of internal medicaion,samsung medical center,Sungkyunkwan University School of Medicine</affiliation>
  </overall_official>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 11, 2013</lastchanged_date>
  <firstreceived_date>June 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Kwang Hyuck Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Lymphatic Diseases</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
